A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression
Status:
RECRUITING
Trial end date:
2027-06-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate how well esketamine nasal spray works in improving depressive symptoms in participants with treatment resistant depression (TRD). This will be assessed by the change from baseline in the Hamilton depression rating scale (HAM-D; 17-item) total score from Day 1 (baseline) to the end of the 4-week treatment phase (Day 28).